Search

Displaying results 5811 - 5820 of 7897 in total
  1. Drug

    RGX-181

    go.drugbank.com/drugs/DB17942
    Experimental

    RGX-181 consists of an adeno-associated virus serotype 9 (AAV9) vector designed to deliver the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1) gene.

  2. Drug

    AVI-7537

    go.drugbank.com/drugs/DB15433
    Investigational

    AVI-7537 is an antisense molecule that binds to the Ebola virus mRNA to prevent the viral replication. … [L46207] AVI-7537 is under investigation in clinical trial NCT01593072 (A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers).

  3. Drug

    RP01

    go.drugbank.com/drugs/DB05751
    Experimental

    RP01 is a novel anti-IgE immunotherapy for allergic individuals. … It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response.

  4. Drug

    IC41

    go.drugbank.com/drugs/DB05776
    Investigational

    IC41 is a therapeutic peptide vaccine. It is being devloped by Intercell AG for the treatment of hepatitis C.

  5. Drug

    alpha-Hydroxy glycineamide

    go.drugbank.com/drugs/DB06568
    Experimental

    It also has an effect on viral gp160 envelope protein. [A31692]

  6. Drug

    Gavestinel

    go.drugbank.com/drugs/DB06741
    Experimental

    Highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM).

  7. Drug

    ALT-2074

    go.drugbank.com/drugs/DB05631
    Investigational

    An organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated.

  8. Drug

    PRO-542

    go.drugbank.com/drugs/DB05793
    Investigational

    PRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells. … PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates.

  9. Drug

    Gallium maltolate

    go.drugbank.com/drugs/DB05420
    Investigational

    Gallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.

  10. Drug

    CT-011

    go.drugbank.com/drugs/DB05916
    Investigational

    CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies.